Highly Rated Avidity Biosciences Hammered After Side Effect Sidelines Study
Yahoo! Finance
The FDA placed a myotonic dystrophy study from Avidity Biosciences on partial hold Tuesday, leading RNA stock to collapse.
Continue Reading